The role of AST-120 and protein-bound uremic toxins in irritable bowel syndrome: a therapeutic perspective.

Abstract

AST-120 (kremezin) exhibits its favourable effects in reducing the levels of renal toxins by selective adsorption of low molecular weight substances from the intestinal lumen. So far, a vast majority of studies were focused on the role of AST-120 in the treatment of chronic kidney diseases and cardiovascular disorders, and positive therapeutic effects of the agent have already been confirmed in clinical conditions. Up to the present, there are only a few studies regarding the role of AST-120 in irritable bowel syndrome (IBS). Compelling data suggest the ability of the compound to adsorb protein-bound uremic toxins and mast cell derived mediators and to modulate the farnesoid X receptor, which is a bile acid sensor indispensable for maintaining homeostasis in the intestine. In this review we focus on the actions of AST-120 on intestinal permeability, reduction of visceral sensitivity and alteration of gut motility. We also discuss whether AST-120 can mitigate common IBS symptoms, such as abdominal pain, bloating and malfunction of the colonic transit and thus improve the quality of life of patients with IBS.

• Authors: Paula Mosińska, Martin Storr, Jakub Fichna
• Journal: Therapeutic advances in gastroenterology (Therap Adv Gastroenterol) Vol. 8 Issue 5 Pg. 278-84 (Sep 2015) ISSN: 1756-283X [Print] England
• PMID: 26327918 (Publication Type: Journal Article, Review)